Rising demand for menopause hormone therapy is exposing a health system that was never built for it. Clinics report waiting lists, while shelves hold fewer products and far fewer answers. Into that gap spill online forums, celebrity endorsements and private prescribers, each improvising a standard of care.
The more uncomfortable truth is that research on menopause biology still lags behind other fields, so treatment protocols rest on a narrow evidence base. Key questions on long‑term thromboembolic risk, breast tissue response to combined oestrogen–progestogen regimens, and optimal dosing for women with cardiovascular comorbidities remain only partially addressed. Into this uncertainty step general practitioners who often received minimal formal teaching on hypothalamic–pituitary–ovarian axis changes or pharmacokinetics of transdermal estradiol, yet are now asked to adjudicate between oral preparations, patches, gels and implants for increasingly informed, impatient patients.
Most contentious of all is training. Medical schools devote limited curriculum time to menopause, while continuing professional development courses tend to follow litigation scares rather than women’s reported needs. Endocrinology and gynaecology specialists debate relative versus absolute risk, but front‑line clinicians face ten‑minute appointments and supply shortages that force non‑ideal substitutions. In this narrow space between demand and knowledge, hormone therapy becomes less a settled science than a live negotiation, with women’s symptoms, and sometimes their trust, as the bargaining chips.
